HCV Patent Case: With "Unclean Hands," Merck Can't Collect Jury Award From Gilead
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead scored a victory in its patent dispute with Merck, in which the latter company was accused by a federal judge of egregious misconduct and being guilty of "unclean hands," and therefore, could not collect the $200m jury award the company had earlier won.
You may also be interested in...
US Supreme Court Declines Review Of False Claims Act, PCSK9, Hep C Patents
Gilead disputed Campie FCA decision, Amgen challenged Repatha ruling, and Merck challenged "unclean hands" defense against damages. Patent and Trademark Office wants court to determine if its attorneys' fees should be covered by patent applicants challenging its decisions.
Does AbbVie Have 'Unclean Hands' From Building Humira Patent Thicket? Judge Allows Discovery
Magistrate judge says Boehringer's theory 'may or may not be viable' as an infringement defense; permits third party subpoenas for information on clinical trials.
Does AbbVie Have 'Unclean Hands' From Building Humira Patent Thicket? Judge Allows Discovery
Magistrate judge says Boehringer's theory 'may or may not be viable' as an infringement defense; permits third party subpoenas for information on clinical trials.